Profound Medical Corp.
PROF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $7 | $7 | $7 |
| % Growth | 41.2% | 7.8% | -2.8% | – |
| Cost of Goods Sold | $3 | $3 | $4 | $4 |
| Gross Profit | $7 | $4 | $3 | $3 |
| % Margin | 65.9% | 60.9% | 45.2% | 43% |
| R&D Expenses | $16 | $14 | $15 | $15 |
| G&A Expenses | $0 | $9 | $9 | $10 |
| SG&A Expenses | $22 | $19 | $18 | $18 |
| Sales & Mktg Exp. | $0 | $9 | $8 | $8 |
| Other Operating Expenses | $0 | $0 | $3 | $0 |
| Operating Expenses | $38 | $33 | $35 | $33 |
| Operating Income | -$31 | -$29 | -$32 | -$30 |
| % Margin | -309.6% | -397.5% | -480.9% | -440.7% |
| Other Income/Exp. Net | $5 | -$0 | $4 | -$0 |
| Pre-Tax Income | -$26 | -$29 | -$28 | -$31 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$26 | -$29 | -$29 | -$31 |
| % Margin | -260.4% | -396.8% | -429.1% | -446.7% |
| EPS | -1.07 | -1.35 | -1.38 | -1.5 |
| % Growth | 20.7% | 2.2% | 8% | – |
| EPS Diluted | -1.07 | -1.35 | -1.38 | -1.5 |
| Weighted Avg Shares Out | 25 | 21 | 21 | 20 |
| Weighted Avg Shares Out Dil | 25 | 21 | 21 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$26 | -$27 | -$27 | -$29 |
| % Margin | -251.7% | -372% | -398.2% | -416.8% |